Navigation Links
Nfocus Neuromedical Announces US Clearance of Unique Guiding Catheter with Uni-body Internal Skeleton
Date:8/18/2009

PALO ALTO, Calif., Aug. 18 /PRNewswire/ -- Nfocus Neuromedical Inc. announced today that the Food & Drug Administration has cleared its novel guiding catheter, the Echo(TM) Distal Access Guiding Catheter, for marketing in the US.

"Nfocus works closely with key clinical opinion leaders to direct all of our design and development projects, and the Echo is our latest success story," said President and CEO Martin Dieck. "Our advisors identified the need for a guiding catheter with improved performance and our team has responded with Echo."

The Echo(TM) Distal Access Guiding Catheter has been cleared by the FDA for introduction of interventional and/or diagnostic devices in peripheral, coronary and neurovascular vessels. A high-quality guiding catheter is required in today's advanced and complex endovascular procedures to assist in reaching the target vessel with stents and other operative devices. The guiding catheter must be atraumatic and flexible within the distant and smaller target vessel - yet provide stable and firm support in the larger vessels where the device enters the body.

"The Echo is a stable platform for placing today's most advanced interventional devices and its unique construction gives it the ability to maintain a round lumen to enable endovascular procedures in very far-reaching vessel locations," continued Mr. Dieck.

"Combined with Echo's earlier CE Mark approval, the US FDA clearance gives Nfocus the ability to enter the top end of interventional guiding catheter markets worldwide. Endovascular surgeons and interventional neuroradiologists will appreciate the supple distal end which resists ovalizing of the lumen and the exceptional support of the proximal section - both produced by the unique catheter skeleton."

About Nfocus Neuromedical Inc.

Nfocus is positioning itself to be the world-wide leader in the development of next-generation endovascular neurosurgery solutions (surgery through less-invasive catheter devices) . Backed by premier venture investors, the Company is developing revolutionary systems to treat neurovascular disease - including brain aneurysms - which are simple, safe, cost-effective and curative.

To learn more about the Nfocus Neuromedical development programs focused on providing faster, simpler and more permanent treatment of vascular diseases of the brain and spine, please visit the Nfocus website: www.nfocusneuro.com.

For more information about aneurysms and hemorrhagic stroke see: www.strokeassociation.org and www.snisonline.org


'/>"/>
SOURCE Nfocus Neuromedical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nfocus Neuromedical Receives CE Mark for the CardioVasc(TM) Stent-Graft and Delivery System
2. Nfocus Neuromedical Announces Acquisition of StarFire Medical
3. Nfocus Neuromedical Elects Eric P. Milledge Chairman of Board
4. National Healthcare Providers Select onFocus epm(TM) To Help Ensure Success on Financial and Strategic Objectives
5. Nfocus Neuromedical Announces European Approval for Novel Guiding Catheter at Society of NeuroInterventional Surgery
6. Nfocus Neuromedical Obtains CE Approval for New Vascular Reconstruction Device
7. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
8. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
9. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
10. HEI, Inc. Announces Sale of RFID Division Assets
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... RawTrition now brings you BioEnergy which ... nutrients from SUPERFOODS! , RawTrition is taking nutrients to the next level! ... the body recognizes its raw form (unlike the synthetically made options that are on ...
(Date:4/26/2017)... ... April 26, 2017 , ... MYOLYN, a medical technology company ... has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for ... Both devices are stationary cycling systems that use MYOLYN’s patent-pending functional electrical ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... committed to raising awareness for Duchenne muscular dystrophy, and funding for Duchenne ... (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne announced today. , ...
(Date:4/25/2017)... ... April 25, 2017 , ... The doctors at Wall Centre Dental ... with dental fear and require sedation to receive dental care. The doctors offer three ... procedures, from hygienic cleanings to oral surgery, at their dental office in Vancouver. Wall ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... in unveiling cutting-edge birth defects research related to Zika virus during pregnancy, as ... premier society for this important science. , The Teratology Society ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017  Novartis today announced the publication of ... and Blood Institute (NHLBI) of the National Institutes ... with treatment-naïve severe aplastic anemia (SAA) achieved complete ... at the initiation of and concurrently with standard ... sequential treatment groups, or cohorts. Cohort 3 added ...
(Date:4/18/2017)... DUBLIN, Ohio , April 18, 2017  Cardinal ... its Non-GAAP 1 fiscal 2017 earnings per share ... 2018 and 2019.  This is in conjunction with this ... Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... EPS from continuing operations will be at the bottom ...
(Date:4/18/2017)... Viverae ® , a leader in workplace wellness technology, ... Watson Campaign Automation, implementing behavioral messaging within the ... experience. Through digital engagement, the platform prompts members to ... The enhanced experience drives engagement by focusing on the ... in their journey to health. Unlike ...
Breaking Medicine Technology: